| 臺大學術典藏 |
2020-07-21T06:25:17Z |
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
|
Shih J.-Y.; Liu Y.-N.;Chang T.-H.;Tsai M.-F.;Wu S.-G.;Tzu-Hsiu Tsai;Chen H.-Y.;Yu S.-L.;Yang J.C.-H.;Shih J.-Y.; Liu Y.-N.; Chang T.-H.; Tsai M.-F.; Wu S.-G.; TZU-HSIU TSAI; Chen H.-Y.; Yu S.-L.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:25:16Z |
Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer
|
Shih J.-Y.; Gow C.-H.;Liu Y.-N.;Li H.-Y.;Hsieh M.-S.;Chang S.-H.;Luo S.-C.;Tzu-Hsiu Tsai;Chen P.-L.;Tsai M.-F.;Shih J.-Y.; Gow C.-H.; Liu Y.-N.; Li H.-Y.; Hsieh M.-S.; Chang S.-H.; Luo S.-C.; TZU-HSIU TSAI; Chen P.-L.; Tsai M.-F. |
| 臺大學術典藏 |
2020-07-21T06:25:15Z |
Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
|
Liu Y.-N.;Tsai M.-F.;Wu S.-G.;Chang T.-H.;Tzu-Hsiu Tsai;Gow C.-H.;Chang Y.-L.;Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; TZU-HSIU TSAI; Gow C.-H.; Chang Y.-L.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:25:14Z |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
TZU-HSIU TSAI; Wu S.-G.; Liu Y.-N.; Yu C.-J.; Shih J.-Y.; Lin Y.-T.; Lin Y.-T.;Tzu-Hsiu Tsai;Wu S.-G.;Liu Y.-N.;Yu C.-J.;Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:11Z |
Discordant HER2 Exon 20 mutation status determines a differential sensitivity to Afatinib
|
Liu Y.-N.; Shih J.-Y.; WEI-YU LIAO; Gow C.-H. |
| 臺大學術典藏 |
2020-07-03T04:00:44Z |
The RssB/RssA two-component system regulates biosynthesis of the tripyrrole antibiotic, prodigiosin, in Serratia marcescens
|
Horng Y.-T.;Chang K.-C.;Liu Y.-N.;Hsin-Chih Lai;Soo P.-C.; Horng Y.-T.; Chang K.-C.; Liu Y.-N.; HSIN-CHIH LAI; Soo P.-C. |
| 臺大學術典藏 |
2020-07-01T08:12:19Z |
ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis
|
Chiu K.-L.;Lin Y.-S.;Kuo T.-T.;Lo C.-C.;Huang Y.-K.;Chang H.-F.;Chuang E.Y.;Lin C.-C.;Cheng W.-C.;Liu Y.-N.;Liang-Chuan Lai;Sher Y.-P.; Chiu K.-L.; Lin Y.-S.; Kuo T.-T.; Lo C.-C.; Huang Y.-K.; Chang H.-F.; Chuang E.Y.; Lin C.-C.; Cheng W.-C.; Liu Y.-N.; LIANG-CHUAN LAI; Sher Y.-P. |
| 臺大學術典藏 |
2020-06-30T08:09:52Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-17T03:01:31Z |
Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C
|
Chang T.-H.;Tsai M.-F.;Gow C.-H.;Wu S.-G.;Liu Y.-N.;Chang Y.-L.;Sung-Liang Yu;Tsai H.-C.;Lin S.-W.;Chen Y.-W.;Kuo P.-Y.;Yang P.-C.;Shih J.-Y.; Chang T.-H.; Tsai M.-F.; Gow C.-H.; Wu S.-G.; Liu Y.-N.; Chang Y.-L.; SUNG-LIANG YU; Tsai H.-C.; Lin S.-W.; Chen Y.-W.; Kuo P.-Y.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-06-16T06:38:12Z |
A psychophysical analysis on perceptual limitation of motion image artifact reduction using 120hz displays
|
Wang, Y.-T.;Liu, Y.-N.;Chien, S.-Y.;Yang, Y.-H.;Chen, Y.-L.;Yeh, S.-L.; Wang, Y.-T.; Liu, Y.-N.; Chien, S.-Y.; Yang, Y.-H.; Chen, Y.-L.; Yeh, S.-L.; SHAO-YI CHIEN |
| 臺大學術典藏 |
2020-05-26T09:26:59Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F;Hsieh M.-S;Wu S.-G;Chang Y.-L;Shih J.-Y;Liu Y.-N;Tsai M.-F;Tsai T.-H;Yu C.-J;Chih-Hsin Yang;Yang P.-C.; Chen Y.-F; Hsieh M.-S; Wu S.-G; Chang Y.-L; Shih J.-Y; Liu Y.-N; Tsai M.-F; Tsai T.-H; Yu C.-J; CHIH-HSIN YANG; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:56Z |
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
|
Shih J.-Y.;Chih-Hsin Yang;Yu S.-L;Chen H.-Y;Tsai T.-H;Wu S.-G;Tsai M.-F;Chang T.-H;Liu Y.-N; Liu Y.-N; Chang T.-H; Tsai M.-F; Wu S.-G; Tsai T.-H; Chen H.-Y; Yu S.-L; CHIH-HSIN YANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Shih J.-Y.;Wen Y.-F;Chih-Hsin Yang;Yang P.-C;Yu C.-J;Chang Y.-L;Tsai M.-F;Liu Y.-N;Wu S-G; Wu S-G; Liu Y.-N; Tsai M.-F; Chang Y.-L; Yu C.-J; Yang P.-C; CHIH-HSIN YANG; Wen Y.-F; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non?�Small-cell Lung Cancer
|
Shih J.-Y.;Chih-Hsin Yang;Wu S.-G;Liu Y.-N;Lin Y.-T; Lin Y.-T; Liu Y.-N; Wu S.-G; CHIH-HSIN YANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-26T09:26:26Z |
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
|
Shih J.-Y.;Chih-Hsin Yang;Yu C.-J;Liu Y.-N;Wu S.-G; Wu S.-G; Liu Y.-N; Yu C.-J; CHIH-HSIN YANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T01:32:59Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
|
YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas
|
Gow C.-H.; Hsieh M.-S.; YEN-TING LIN; Liu Y.-N.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:56Z |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
Shih J.-Y.;Yu C.-J.;Liu Y.-N.;Wu S.-G.;Tsai T.-H.;YEN-TING LIN; YEN-TING LIN; Tsai T.-H.; Wu S.-G.; Liu Y.-N.; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:43Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non�VSmall-cell Lung Cancer
|
Shih J.-Y.;Yang J.C.-H.;Wu S.-G.;Liu Y.-N.;YEN-TING LIN; YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Validation of immunohistochemistry for the detection of BRAF V600E-mutated lung adenocarcinomas
|
Shih J.-Y.;Liu Y.-N.;YEN-TING LIN;Hsieh M.-S.;Gow C.-H.; Gow C.-H.; Hsieh M.-S.; YEN-TING LIN; Liu Y.-N.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4�VALK Rearranged Non-small Cell Lung Cancer
|
Shih J.-Y.;Liu Y.-N.;YEN-TING LIN; YEN-TING LIN; Liu Y.-N.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:41Z |
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
|
Shih J.-Y.; Yu C.-J.; Liu Y.-N.; Wu S.-G.; Tsai T.-H.; YEN-TING LIN; Shih J.-Y.;Yu C.-J.;Liu Y.-N.;Wu S.-G.;Tsai T.-H.;YEN-TING LIN |
| 臺大學術典藏 |
2020-03-07T06:56:27Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.;Hsieh M.-S.;Wu S.-G.;Yih-Leong Chang;Shih J.-Y.;Liu Y.-N.;Tsai M.-F.;Tsai T.-H.;Yu C.-J.;Yang J.C.-H.;Yang P.-C.; YIH-LEONG CHANG; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Chen Y.-F.; Hsieh M.-S.; Wu S.-G. |
| 臺大學術典藏 |
2020-03-07T06:56:18Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Wu S-G.; Liu Y.-N.; Tsai M.-F.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
